Intractable Helicobacter Pylori Infection in Female Persons of Child-Bearing Age: Clinical, Surgical and Socioeconomic Implications

The contribution of this research is dependent on its strength and drive to prominent discussion on the persistent public health challenges, issues, opportunities and priorities posed by antibiotic-resistant H. pylori infections, within clinical, surgical and socioeconomic expansive system-level solutions within the scientific community and publication health contexts. . Intractable Helicobacter pylori (H. pylori) infection in female persons of child-bearing age presents defined clinical risks, potential surgical emergencies, and adverse economic burdens. As the bacterium demonstrates resistance to traditional antibiotic modalities, the persistent inflammatory response invariably impairs both maternal health and reproductive outcomes. Clinical aspects of intractable Helicobacter pylori (H. pylori) on female persons of child-bearing age takes into cognizance management of the infections which require equilibrating aggressive bacterial eradication against teratogenicity risks. It is pertinent that standardised salvage regimens are profoundly modified at pregnancy in active or planned pregnancy. The clinical impacts and risks of intractable H. pylori infections present distinct risks to this precise cohort, especially considering maternal-foetal outcomes. Studies depict strong correlations between dynamic maternal infection and adverse gestational sequelae. Surgical intervention for complications of intractable Helicobacter pylori sequelae conveys indepth morphological, nutritional, and reproductive impacts for female persons of child-bearing age. While surgery may not strictly expunge the H. pylori bacterium, it is extricated for life-threatening refractory instances, such as perforated peptic ulcers, exceptional bleeding, or gastric outlet obstruction. In women of reproductive age, these radical gastrointestinal surgeries exert intricately complex challenges and issues which entail micronutrient depletions, metabolic alterations, and pregnancy risks of specialty spheres. Intractable maternal morbidities with consequential unintended pregnancies exert prolonged economic burdens on female persons of child-bearing age with permanent restriction of their educational achievement and attainment, depreciation of lifetime labour market productivity, and induction of catastrophic out-of-pocket medical indebtedness and expenses. As clinical or socioeconomic conditions culminate in intractable (unmanageable or persistent) states, these progressively trigger a cumulative compounding cycle of financial distress and restrictions of female persons of child-bearing age, especially young, low-income, or marginalized women entrapped in excruciating systemic poverty and community of inequitable distribution of resources. This work attempts to explore the complex interaction between intractable Helicobacter pylori (H. pylori) infection and adverse outcomes in women of childbearing age. The topic exudes substantial public health importance due to its consequences for both maternal and foetal health, and expansive socioeconomic impacts. The focus on antibiotic resistance and the potential mandate for surgical intervention offers critical insights for managing H. pylori in vulnerable populations. H. pylori remains a public health challenge and issue, and it geopolitically exists as an emerging and reemerging infectious concern of morbidity and mortality with increased transmission, dissemination and gross under-ascertainment of its geopolitical encumbrance.

Export Citation CrossMark Publons Harvard Library HOLLIS GrowKudos Search IT Google Scholar Academic Microsoft Scilit Semantic Scholar Universite de Paris UW Libraries SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat DTU VU on WorldCat ResearchGate

Helicobacter pylori (H. pylori) infection was unravelled in early 1982; and it was prevalent in developing countries in comparison to developed countries. H. pylori is a gram-negative bacillus colonized in the stomach and functions actively in the diverse gastrointestinal diseases or disorders as the most ubiquitous acute and chronic infection globally [1,2] such as peptic ulcers and gastric carcinoma particularly in late adulthood [3] Thus, globally, Helicobacter pylori infection constitutes itself as a ubiquitous anomaly perturbing humans. It is the aetiologic agent of chronic gastritis, duodenal and gastric ulcers, and is a significant risk factor for gastric cancer in later life. H. pylori carves a niche for third placement in the Priority High category in the list of World Health Organization (WHO) antibiotic-resistant priority pathogens. These are bacteria posing profound threat to human health because of their resistance to multitudinous antibiotics. Globally, Helicobacter pylori infestation perturbs circa 50% of our population and the principal aetiological agent of excruciating gastric disorders, such as peptic ulcers and gastric carcinoma. Infection primarily results from person-to-person contact, predominantly in crowded housing situations, and access to H. pylori contaminated drinking water [4]. The paucity of a convenient source for vaccine against H. pylori is of major concern taking into cognizance the expansive characteristics of the infection and the potential sequelae. Current evidence regarding how H. pylori infection may influence obesity and diabetes, how metabolic diseases may affect the persistence or prevalence in the therapeutic course of diabetes, obesity [5,6] and Helicobacter pylori infection [3] in female persons of child-bearing age.

Vulnerable communities enmeshed in penury and certain climatic zones [7-10] are significantly affected by H. pylori infection. Although, there have been certain therapeutic impact of infected persons, and decrement in the transmission of infection in ambients where socioeconomic living standards have progressed, H. pylori incessantly constitutes an expansive ubiquitous human bacterial pathogen worldwide, thus presenting as a significant aetiology of morbidity and mortality globally. When therapy does not succeed towards H. pylori, it culminates in procrastination to expunge the infection, creating more latitude and opportunity for inflammation, potentiating progressive precancerous stages and resultant advanced-stage cancer, tremendously associated with inadequate therapeutic outcomes and mortality. Critically, while merely AMR strictly is not an aetiology of cancer, it provide an intricately complex stage wherein therapy of the infection becomes cumbersome with resultant persistent inflammation and potentiate contribution to cancer risk [11] Intractable Helicobacter pylori (H. pylori) infection in female persons of child-bearing age generates gross clinical risks, potential requirements for surgical intervention, and escalated financial burden. With resistance of the infection to conventional antibiotic regimen it extensively progresses more than rudimentary gastrointestinal discomfiture invariably impinging reproductive health, pregnancy outcomes, and long-run socio-economic productivity and essence.

This article focuses on the challenges presented by intractable H. pylori infections in women of childbearing age, with emphasis on the bacterial resistance to antibiotics and its potential to disrupt and distort reproductive health. Through detailed exploration of pathophysiology of H. pylori infection, the study intimates that surgical interventions, hough invasive, may sometimes require application. The socioeconomic implications of these persistent infections are evaluated, highlighting the financial and educational burdens encountered by affected women of reproductive age. Importantly, the work is dependent on the premise that elevating resistance correlates to surrogate therapeutic strategy and source.

Parametrics of helicobacter pylori

Helicobacter pylori (H. pylori) is a gram-negative bacterium that infects the stomach, impairs the tissue in the stomach and the first aspect of the small intestine, the duodenum, with resultant pain and inflammation. Furthermore, in certain instances, it produces painful sores named peptic ulcers in the upper digestive tract. A vast majority of those who bearing it may not present ulcers or indicate any symptoms but it is a major aetiology of ulcers. H. pylori causes denudation of the lining protecting the stomach. The bacterium produces urease, an enzyme that ameliorates acidity of stomach acids, as it denigrates the stomach lining. Thus, the stomach cells become susceptible to greater risk of being excoriated by acid and pepsin, powerful digestive fluids, resulting in sores or ulcers in the duodenum or stomach. The H. pylori bacteria can also adhere to stomach cells, as the stomach cannot protect itself adequately. The affected portion undergoes inflammation, with concomitant production of more acid by H. pylori that is unable to be explicated or elucidated. An intractable H. pylori infection induces a chronic condition of systemic inflammation that depicts definite sequelae for female patients [12].

Helicobacter pylori is part of a genus of specialized bacteria with adaptation to the ecological niche provided by gastric mucus, with exploitation of the human niche, as additional species of Helicobacter inhabit the gastric mucosa of other animals. The favoured habitat of H. pylori is the gastric antrum. In individuals with normal gastric function, the organism is preferably confined to the antral surface, where diverse specialized characteristics grant the bacteria latitude to proliferate, exerting minimal impairment to its host. These encompass a specific motility that permits it to swim quickly in viscous mucus, and the potential to produce extensive quantities of the enzyme, urease. Urease functions by degrading endogenous urea to create ammonia, which conveys protection on the bacterium from gastric acidity. Special adhesions adhere certain of the bacteria to the gastric surface, while certain of them liberally frolic in the mucus, and others probably endocytose into the epithelial cells. Possibly, these inaccessible colonization terrains cause the organism not to be easily expunged. In certain patients, the generally innocuous equilibrium between host and bacterium is perturbed, culminating in peptic ulceration [11-13]. Alterations to the mucus or epithelial surface in the proximal duodenum impacting the gastric phenotype cause the tissue to be extensively vulnerable to H. pylori infection of the duodenum by disseminating organisms from the antrum. Gastric acid output becomes greatly elevated, and the duodenal mucosa is subjected to more vulnerability to acid stress, with resultant peptic ulceration. Within other conditions, the inflammation magnitude is aggravated leading to immunopathology, accompanied later in certain instances by atrophy and gastric cancer [13].

Global prevalence:of Helicobacter pylori

Erstwhile estimates indicate that approximately 4.4 billion persons contracted H. pylori infection globally in 2015, with highest incidence in Nigeria. In other countries, such as Japan, China, Korea, and Taiwan [11] researchers are focusing on R&D prowess to circumvent the challenges and issues exerted by H. pylori, with higher rates in developing nations. Even if these tend to be or are asymptomatic, it translates to billions of persons creating ecological niches for the bacteria. Although, most infected persons are asymptomatic, H. pylori intrusion and infection can lead to severe health challenges and issues,. Excruciatingly uncomfortable sores in the duodenum or stomach, impacting inordinate number of persons worldwide. Gastritis occurs as the stomach lining inflammation featuring discomfort and potential haemorhaging. Chronic H. pylori infection constitutes an adverse major risk factor for lethal cancer. H. pylori is rapidly becoming resistant to normal antibiotics, causing effective therapy to be increasingly problematic. Extant therapeutic regimens inculcate multitudinous medications, rising compliance challenges, issues and potential side effects and untoward oucomes. H. pylori- associated sequelae correlates with a profound socio-economic burden on healthcare systems globally, with resultant Increased healthcare costs; decrement in quality of life for affected persons in vulnerable populations and low-income families; potential economic dissipation due to prolonged morbidity, comorbidity and subsequent mortality.

The non-availability of a vaccine creates pronounced lacunae in prevention and control modalities. Progressive R&D efforts are critical in addressing the challenge, issues, opportunities and priorities related to this concern. Although, a gross availability of vaccine remains non-extant, there are advances in trajectories for interventions for the future: Improvement in diagnostics results when accelerated and more accurate detection procedures can eradicate retardation of early intervention. Alternative therapeutic regimens: Examining non-antibiotic strategies to expunge H. pylori. Advanced and progressive research: Incessant efforts focused on the development of effective and efficacious vaccines remain extant [11].

Awareness raising regarding H. pylori, its aetiology, prevention, sequelae and the pertinence for effective remedies must take precedence and be prioritised concomitantly with other gastric ailments. Most important is to eradicate or expunge the misleading stance that peptic, duodenal, gastric, stomach or other ulcers may be strictly due to hunger pangs. Undergirding research efforts, advocating and soliciting for funding could progressively expedite better and improved prevention and control modalities against dual intricate complexities, such as cancer upsurge and antibiotic-resistant H. pylori.

Athough, acute H. pylori infection may not be directly associated with oncological dilemma, chronic H. pylori infection invariably constitutes a major risk factor for stomach or gastric cancer. While merely AMR is not a direct aetiology for cancer, it enacts an enigmatic scenario whereby treatment of the infection becomes elusive and cumbersome, culminating in opportunity for persistence of the inflammation and potential contribution to cancer risk. H. pylori treatment necessitates multidrug regimens due to resident niche of the organism in a layer of mucus that impedes antibiotic penetration, such as amoxicillin, erythromycin, clarithromycin and metronidazole. The bacterium resistance to conventional antibiotics, such as clarithromycin or metronidazole, therapy antecedent to or during pregnancy becomes extremely problematic [14,15].

Statistically significant association between H pylori infection with correlated attributes among pregnant women indicated that 80% of persons became infected in developing countries. Pregnant women are mostly susceptible to H. pylori infection [16]. The infection correlates to lower socioeconomic status, inadequate sanitation, absence of safe drinking water, and sequelae such as severe anaemia and gastrointestinal morbidities. Multiple people can be immensely vulnerable to H. pylori because of immune alterations and decreased stomach acid causing the infection a pronounced public health concern [17-20]. This places children from infected women of productive age at risk for diarrhoea, malabsorption of critical nutrients, vitamin C and B12, as well as growth and development.

Progression Stages of H. pylori infection

Typically, it spans decades, from 20 to 40 years for chronic, untreated infection for Helicobacter pylori (H. pylori) to cause stomach cancer. The vast majority of people infected with the bacteria will hardly succumb to cancer, however, protracted inflammation slowly alters the stomach lining more than a clearly scannable and retarded timeline. Initial Infection usually appears in childhood and induces progressive swelling and irritation as chronic gastritis. Helicobacter pylori occurs as a pathogen associated with peptic ulcers and gastric carcinoma. Certain studies depicted that the infected pregnant women with H. pylori have poor pregnancy outcomes, causing its impacts to extrapolate to extraneous systems not gastrointestinal tracts [21]. Mid-Stage degradation beyond several years, exhibits that the persistent irritation results as overt sores, peptic ulcers or permanent thinning of the stomach lining, atrophic gastritis. Precancerous alterations expose that normal stomach cells slowly metamorphose into abnormal sorts of metaplasia and dysplasia following extended periods of degradation. In rare instances, these incurable cellular alterations metamorphose into unrestricted growth (malignancy) or stomach cancer.

Risk and prevention factors attributed to Helicobacter pylori

Accelerating attributes, such as smoking tobacco, diet excessive in salty or processed edibles, and a family history of stomach cancer can accelerate or exacerbate the cellular impairment [22]. Therapeutic actions due to consumption of short courses of antibiotics can eradicate the bacteria and significantly mitigate a long-term cancer risk.

Clinical impacts and reproductive vulnerabilities

An intractable infection triggers a condition of chronic, systemic inflammation that confers defined sequelae for female patients:

The table below depicts the integral impacts encompassing clinical, surgical, and economic spheres for this characteristic demographic group.

───────────────────────────────────┐
│ Intractable H. pylori in Childbearing Women │
└───────────────┬──────────────────┘
┌───────────────┼────────────────┐
▼                                             ▼                                            ▼
┌──────────┐┌─────────┐┌──────────┐
│Clinical Impacts ││Surgical Impacts ││ Economic Burden │
├──────────┤├─────────┤├─────────┤
│• Hyperemesis ││• Perforated ││• High direct │
│ gravidarum ││ ulcers ││ rescue therapy │
│• Severe iron ││• Gastric outlet ││ costs │
│ deficiency ││ obstruction ││• Career/wage │
│• Preeclampsia & ││• Marginal ulcers││ losses from │
│ foetal growth ││ after gastric ││ maternal │
│ restriction ││ bypass surgery ││ disability │
└──────────┘└────────┘└───────────┘

Impact Dimension Primary Manifestations Key Complications / Drivers

Clinical• Adverse refractory anaemia• Hyperemesis gravidarum (HG)• Excruciatingpregnancy outcomes• Deficient iron and Vitamin B12 storage• Unmitigated pregnancy-associated vomiting• Preeclampsia (eclampsia), miscarriage, and foetal growth restriction (FGR).

Surgical• Perforated peptic ulcers• Gastric outlet obstruction• Severe upper GI bleeding• Emergency laparoscopy or laparotomy• Endoscopic balloon dilation or pyloroplasty• Urgent endoscopic haemostasis or resection.

Economic• High direct medical costs• Indirect productivity losses• Subfertility & ART failure costs• Repeated rescue therapies and endoscopies• Workplace absenteeism and disability• Wasted In Vitro Fertilization (IVF) / ICSI cycles.

*There are no clear extant guidelines for screening or treating H. pylori in pregnancy.

Clinical implications and reproductive risks associated with H. pylori

Intractable H. pylori strains incessantly induce systemic pro-inflammatory cytokines, causing extra-digestive sequelae which profoundly disrupt female physiological [23] disposition and functionality. This persistent, drug-resistant H. pylori induces both arduous localized gastrointestinal symptoms and extreme systemic dysfunctions in reproductive-aged female. Severe iron-deficiency anaemia (IDA) occurs as H. pylori sequesters dietary iron and creates chronic micro-bleeding. During menstruation of female persons, this aggravates blood loss, culminating in anaemia that is highly resistant to oral iron supplementation [24].

Helicobacter pylori infection during pregnancy

Helicobacter pylori infection presents systemic inflammatory, metabolic, and endothelial impacts more than the digestive tract. In pregnancy, these processes may aggravate disparate maternal sequelae in the extra-digestive impact of H. pylori infection in pregnancy. Helicobacter pylori infection is associated with major extraneous digestive sequelae in pregnant women. Infection may exacerbate iron-deficiency anaemia and suppress response to supplementation. H. pylori is associated with elevated risk and aggravated gestational diabetes mellitus[25,26]. The infection may promote preeclampsia through endothelial and angiogenic distortions and disruptions.

Clinical impacts and obstetric complications

Intractable H. pylori shifts from a localized gastric issue to a systemic pathogen with particular risks for women of reproductive age in the 15–49 years range. Severe maternal malnutrition and anaemia refractory iron-deficiency anaemia (IDA) are evidenced as H. pylori invariably competes for maternal iron stores and debilitates gastric acid secretion that impedes oral iron absorption. In this scenario, women with menstrual blood loss or pregnancy demands, exhibit anomalous and treatment-resistant anaemia. Significantly, hyperemesis gravidarum (HG) cause intractable infections to significantly elevate the severity and persistence of extreme morning sickness. Hormonal alterations during pregnancy potentiate latent H. pylori, culminating in abysmal fluid dissipation, critical electrolyte disequilibria, and prolonged hospitalisation [16]. Adverse pregnancy and neonatal outcomes of preeclampsia are established in the systemic inflammation and molecular mimicry initiated by virulent H. pylori strains, specifically as CagA-positive aetiologically impact maternal endothelial dysfunctionality and anomalous placental vascularization, aggravating preeclampsia risk [27]. Foetal growth restriction (FGR) and low birth weight are associated with chronic maternal cytokine discharge and localized placental inflammation which restrict vital nutrient transport, resulting in impaired foetal development, low birth weight, or intrauterine foetal mortality [28]. Early pregnancy termination result due to active, unrelenting maternal infections, and are inextricably-linked to spontaneous miscarriages and early pregnancy dissipation during the first 12 weeks of gestation [29]. The treatment paradox in pregnancy as observed in the management of intractable H. pylori in pregnancy is extremely challenging. Conventional salvaging therapies, for instance, rescue regimens employing tetracycline, levofloxacin, or bismuth are exposed to adverse risks of foetal toxicity and congenital abnormalities. Consequentially, clinicians are frequently compelled to retard effective expungement until post-delivery, for the mother to confront high-risk clinical symptoms within the gestational period [30].

Succinctly, the systemic repercussions of a chronic, therapy-resistant infection intersect critically with female reproductive physiology, maternal-foetal outcomes, and economic labour productivity. An intractable H. pylori infection arduously disrupts both maternal health and foetal development via chronic inflammation and nutrient decrement. Maternal obstetric sequelae exhibits as hyperemesis gravidarum (HG) and manifests as refractory H. pylori that prominently elevates the risk and severity of HG, with resultant grave fluid, electrolyte, and nutritional depletions which frequently demand hospitalization. The systemic, pro-inflammatory cytokine discharge induced by chronic, virulent strains culminate in preeclampsia challenge.

Surgical and interventional implications

As H. pylori becomes intransigently intractable to medications, the risk of tissue deterioration escalates, resulting to acute or elective surgical interventions [31]. Perforation and peritonitis result in resistant healing and profound peptic ulcers can excoriate or denude the stomach or duodenal wall, necessitating emergency laparoscopy or laparotomy to conduct an omental (Graham) patch reparation. Refractory gastrointestinal haemorrhage from persistent and incessant erosive processes into major gastric blood vessels can cause life-threatening bleeding. With unsuccessful therapeutic endoscopy, open surgical ligation or partial gastrectomy is pertinent. Gastric outlet obstruction emanating from chronic cycles of ulceration and scarring in proximity to the pylorus lead to mechanical strictures, requiring surgical pyloroplasty or gastrojejunostomy to reinvigorate digestive flow. Malignant transformation aetiologically emanating as a result of extended intractable infection is a primordial driver of gastric adenocarcinoma and MALT lymphoma, necessitating oncological resections, such as subtotal or total gastrectomy further in life. When antibiotic expungement therapy reiteratively denigrates, clinical management shifts from standard pharmacology or medications [32] to invasive diagnostic and emergency surgical interventions. Due to the refractory nature of H. pylori to medical eradication, gastric mucosa degradation can progress to levels where emergency or elective surgery becomes compulsory. Reiterative endoscopic surveillance in intractable cases necessitate serial esophagogastroduodenoscopy (EGD) procedures to garner or extract gastric biopsies for specialized antimicrobial vulnerability testing, culture [33] and procedures.

Intractable Helicobacter pylori (H. pylori) infection in women of reproductive age poses indepth clinical, obstetric, and surgical risks, while obfuscating pertinent, personal and macroeconomic burdens. Since antibiotic resistance causes eradication to be increasingly complex, chronic systemic inflammation and nutrient depletions severely debilitate both maternal health and foetal development. As the bacterium enacts resistance to standard antibiotics, its persistence shifts from the commonplace gastrointestinal challenge and issue into a systemic reproductive health opprobrium. It advances from a restricted gastric enigma into a systemic stressor with never-ending physical and pecuniary constraints [34]. Colonisation of persistent and therapy-resistant mode induce a cascade of systemic gestational sequelae that enhances the propensity for high-risk surgical interventions, with imposition of excruciating financial dissipation and encumbrance on healthcare systems and households. Extant findings suggest H. pylori infection contributes to iron-deficiency anaemia, gestational diabetes and preeclampsia through interconnected inflammatory and vascular mechanisms. Although, the aetiology is inconclusive, targeted screening and personalised monitoring and evaluation strategies may be given cognizance in specialised high-risk, as the risk of tissue degradation and neoplastic transformation aggravates in preparedness for aggressive surgical interventions during the peak reproductive years of a female person.

├─► Severe Gastric Ulceration ──► Perforation/Hemorrhage ──► Emergency Laparotomy│

└─► Persistent Mucosal Damage

[Chronic Intractable H. pylori]

─► Severe Gastric Ulceration ──► Perforation/Hemorrhage ──► Emergency Laparotomy

└─► Persistent Mucosal Damage ──► Gastric Adenocarcinoma ──► Gastrectomy & Oophorectomy

Emergency surgery for peptic ulcer disease (PUD) is necessary in refractory mucosal ulceration to suppress accelerating to acute sequelae, such as gastric perforation or uncontrollable upper gastrointestinal hemorrhage [35]. These life-threatening scenarios demand emergency laparotomy or laparoscopic repair, for instance, Graham patch omental repair. Prophylactic oophorectomy and sterility become mandatory in cases wherein gastric adenocarcinoma pertains, and transcoelomic metastasis risk progresses [36] to the ovaries (Krukenberg tumours). Surgical management normally involves bilateral oophorectomy, culminating in surgical menopause and unquestionable sterility. Surgical procrastination and teratogenic risks are associated with mandatory surgical interventions during pregnancy that depict significant anaesthesia risks for the foetus. Obversely, radical surgeries for cancer need pregnancy termination or retardation of lifesaving maternal therapeutic measures [37].

H. pylori-induced economic burden on women of reproductive age

The resultant perilous economic impact of intractable H. pylori is expressed in the demographic strangulation of both personalised households and healthcare systems, highlighted by productivity decline during peak working years The economic repercussions of a refractory infection disproportionately disrupt and distort the quality of life for pregnant womeni [38].

├──► Direct Costs ──► Repeated Salvage Therapies & Endoscopies

├──► Indirect Costs ──► Lost Productivity & Maternal Absenteeism

└──► Intergenerational ──► Neonatal ICU Admissions & Transmission Care

Direct Medical Costs Escalation: Patients encounter sequential expenditures on expensive salvage antibiotic regimens, susceptibility testing, and frequent monitoring through upper endoscopies.

The dissipation of workforce productivity depict excruciating symptoms and frequent medical visitations culminating in extensive workplace absenteeism, which negatively impact women of reproductive age during their peak career and earning capability [38]. Intergenerational financial strain enhance poor birth outcomes, such as preeclampsia, eclampsia and low birth weight which oftentimes exert extensive and expensive neonatal intensive care unit (NICU) residence. Intra-familial transmission costs affect the functionality of Infected mothers of reproductive as primary vectors for intra-familial transmission. The consequence is the formulation of a concomitant intricately complex rigmarole of paediatric infection expenditures within the households.

Insightful in this study is the comprehensive review of the clinical, surgical and socioeconomic complexities aetiologically attributed to H. pylori infections among reproductive age women. This aptly highlights the unresolved challenges, issues, opportunities and priorities of antibiotic resistance and the resultant sequelae these pose for therapeutic approaches. The interlinkage of the medical, surgical, and financial spheres of the infection enhances profundity to the topic and advances its relevance to public health policy. Moreover, inculcating global prevalence and vulnerabilities expose the expansive and expensive nature of the intricacies [39-41].

1. Chukwuma Sr C. Syndemics of chronic and acute diseases in vulnerable populations. Acta Med Sci. 2017;4(1). Available from: https://www.researchgate.net/publication/363136099_Syndemics_of_chronic_and_acute_diseases_in_vulnerable_populations
2. Chukwuma Sr C. The complexity of communicable and non-communicable diseases in vulnerable populations. ABBSR. 2020;3(1). Available from: https://www.opastpublishers.com/table-contents/abbsr-volume-3-issue-1-year-2020
3. Goh KL, Chan WK, Shiota S, Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2011;16 Suppl 1:1-9. Available from: https://doi.org/10.1111/j.1523-5378.2011.00874.x
4. Chukwuma Sr C. Environmental and social consequences of metals and mines on water. Int J Environ Stud. 1998;54(1):73-81. Available from: https://www.tandfonline.com/doi/abs/10.1080/00207239808711140
5. Chukwuma Sr C. Development and implementation of environmental monitoring and information systems for water resources. Environ Manage Health. 1998;9(4):153-159. Available from: https://www.researchgate.net/publication/243463748_Development_and_implementation_of_environmental_monitoring_and_information_systems_for_water_resources
6. Chukwuma Sr C. To what extent for improved water supply? Int J Adv Res Biol Sci. 2020;7(12):i-ii. Available from: https://www.researchgate.net/publication/347906585_To_What_Extent_for_Improved_Water_Supply
7. Chukwuma Sr C. Reflections and perspectives on the determinants for risk reduction in biodiversity, environment and health vulnerabilities due to climate change and extreme hydrological events: an ecological framework. Greenfort Int J Appl Med Sci. 2025;3(3). Available from: https://www.researchgate.net/publication/392601673_Reflections_and_Perspectives_on_the_Determinants_for_Risk_Reduction_in_Biodiversity_Environment_and_Health_Vulnerabilities_Due_To_Climate_Change_and_Extreme_Hydrological_Events_An_Ecological_Framework
8. Chukwuma Sr C. Invariance of extreme hydrologic events and climate change in the risk reduction on environment and health. Greenfort Int J Appl Med Sci. 2025;3(2). Available from: https://bishtref.com/articles/10.62046/gijams.2025.v03i02.011
9. Chukwuma Sr C. The prevalence of fissured peace, justice and sustainable development in Nigeria and other developing countries. Greenfort Int J Appl Med Sci. 2025;3(4). Available from:
10. Chukwuma Sr C. Correlated critical risk reduction of invariance challenges and issues concerning extreme hydrologic events and climate change on environment and health. J Public Health Care Res Epidemiol. 2025;1(2). Available from: https://www.academia.edu/143710798/Correlated_Critical_Risk_Reduction_of_Invariance_Challenges_and_Issues_Concerning_Extreme_Hydrologic_Events_and_Climate_Change_on_Environment_and_Health
11. Ashwin A. Helicobacter pylori, cancer and AMR. The Microbiologist. 2024. Available from: https://www.the-microbiologist.com/features/helicobacter-pylori-cancer-and-amr/2654.article
12. Alsharidah A, Mansour JMA. Impact of Helicobacter pylori infection on metabolic and physiological parameters among young adults individuals. J Clin Med. 2026;15(11):4046. Available from: https://doi.org/10.3390/jcm15114046
13. Lee A. The microbiology and epidemiology of Helicobacter pylori infection. Scand J Gastroenterol Suppl. 1994;201:2-6. Available from: https://www.tandfonline.com/doi/abs/10.3109/00365529409105352
14. Wanyama R, Obai G, Odongo P, et al. Effect of maternal Helicobacter pylori infection on gestational weight gain in an urban community of Uganda. Pan Afr Med J. 2017;28:145. Available from: https://doi.org/10.11604/pamj.2017.28.145.9989
15. Franco A, Shihadeh K. H. pylori infection: resistance and recommendations for treatment. Healio. 2022. Available from: https://www.healio.com/news/infectious-disease/20220407/h-pylori-infection-resistance-and-recommendations-for-treatment
16. Yisak H, Belete D, Mahtsentu Y. Helicobacter pylori infection and related factors among pregnant women at Debre Tabor General Hospital, Northwest Ethiopia, 2021: anemia highly related with H. pylori. Womens Health (Lond). 2022;18:17455057221092266. Available from: https://doi.org/10.1177/17455057221092266
17. Chukwuma Sr C. Public health concerns of GLP-1 receptor agonists in the treatment of type 2 diabetes and obesity patients. Biomed J Sci Tech Res. 2026;66(4):BJSTR.MS.ID.010363.
18. Chukwuma Sr C. Probing the emergence and re-emergence of infectious diseases, geopolitics and gain-of-function research. Chem Sci Eng Res. 2021;3(8):66-71. Available from: https://www.researchgate.net/publication/358149023_Probing_the_Emergence_and_Re-emergence_of_Infectious_Diseases_Geopolitics_and_Gain-of-Function_Research
19. Chukwuma Sr C. Cryptosporidium: public health problems and environmental indicators. Austin Med Sci. 2019;4(2):1036. Available from: https://austinpublishinggroup.com/medical-sciences/fulltext/ams-v4-id1036.php
20. Chukwuma Sr C. Convergence in diplomacy, geopolitics and international cooperation for human health and environment. J Biomed Res Environ Sci. 2022;3(8):895-904. Available from: https://www.jelsciences.com/articles/jbres1529.php
21. Zanzal R Al-D A, Ibraheem SN, Saleh KH. Serological detection of Helicobacter pylori infection in pregnant women related to ABO blood group. Arch Razi Inst. 2022;77(2):591-597. Available from: https://doi.org/10.22092/ari.2022.357092.1970
22. Rhee KH, Park JS, Cho MJ. Helicobacter pylori: bacterial strategy for incipient stage and persistent colonization in human gastric niches. Yonsei Med J. 2014;55(6):1453-1466. Available from: https://doi.org/10.3349/ymj.2014.55.6.1453
23. Cardaropoli S, Rolfo A, Todros T. Helicobacter pylori and pregnancy-related disorders. World J Gastroenterol. 2014;20(3):654-664. Available from: https://doi.org/10.3748/wjg.v20.i3.654
24. Besnier M, Joseph JY, Laurandeau A, et al. The impact of Helicobacter pylori infection on pregnancy: a narrative review. Eur J Obstet Gynecol Reprod Biol. 2026;325:115279. Available from: https://doi.org/10.1016/j.ejogrb.2026.115279
25. Chukwuma Sr C. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) correlated with mitigated risks of early mortality, cardiovascular and renal risks in type 1 diabetes (T1D) subjects: perspectives on the economic impact. Medico Res Chron. 2026;13(3):435-446. Available from: doi:10.26838/MEDRECH.2026.13.2.917.
26. Chukwuma Sr C. Exploring advances in interdisciplinary research explicating shared reciprocal interplay and intersections between ageing, diabetes, (re)emerging infections, clinical implications and therapeutics. Case Rep Int J. 2026;4(1). Available from: https://aditum.org/images/currentissue/1775715400CRIJ-Galley_Proof.pdf
27. Ghasemi-rad M, Memari A, Naji S, Mladkova N, Saeedi V. Effect of Helicobacter pylori infection on pregnancy rates and early pregnancy loss after intracytoplasmic sperm injection. Int J Womens Health. 2011;3:329-335. Available from: https://doi.org/10.2147/ijwh.s24424
28. Wang SJ, Hsieh CJ, Su YH, et al. Assessment of adverse pregnancy outcomes associated with Helicobacter pylori infection. Sci Rep. 2024;14:32023. Available from: https://doi.org/10.1038/s41598-024-83694-9
29. Li J, Fan M, Ma F, Zhang S. The effects of Helicobacter pylori infection on pregnancy-related diseases and fetal development in diabetes in pregnancy. Ann Transl Med. 2021;9(8). Available from: https://doi.org/10.21037/atm-21-1209
30. Zefenkey Z. Association between Helicobacter pylori infection and pregnancy-related complications. Cihan Univ Erbil Sci J. 2026;10(1):63-68. Available from: doi:10.24086/cuesj.v10n1y2026.pp63-68.
31. Zhou B, Wang F. Research progress in relation of Helicobacter pylori infection with pregnancy-related diseases and adverse pregnancy outcomes. J Fourth Mil Med Univ. 2020;45(3):338-344. Available from: https://doi.org/10.11817/j.issn.1672-7347.2020.190032
32. Chukwuma Sr C. Interdependencies and feedback loops: information-base for the effective evaluation on how nature and anthropogenic activities shape global health and environment in ecosystem dynamics (ecodynamics). World J Pharm Healthc Res. 2026;3(6):1-9. Available from: doi:10.5281/zenodo.21735423.
33. Aljarad S, Alhamid A, Tarabishi AS, et al. The impact of Helicobacter pylori eradication on platelet counts of adult patients with idiopathic thrombocytopaenic purpura. BMC Hematol. 2018;18:28. Available from: https://doi.org/10.1186/s12878-018-0119-y
34. Salih BA. Helicobacter pylori infection in developing countries: the burden for how long? Saudi J Gastroenterol. 2009;15(3):201-207. Available from: https://doi.org/10.4103/1319-3767.54743
35. Santos LKS, Apolonio JS, Cuzzuol BR, da Costa BT, Lima de Souza Gonçalves V, da Silva Júnior RT, et al. Helicobacter pylori infection in pregnant women: gastrointestinal symptoms and pregnancy-related disorders. World J Clin Infect Dis. 2023;13(5):49. Available from: doi:10.5495/wjcid.v13.i5.49.
36. Cardaropoli S, Giuffrida D, Piazzese A, Todros T, et al. Helicobacter pylori seropositivity and pregnancy-related diseases: a prospective cohort study. J Reprod Immunol. 2015. Available from: https://doi.org/10.1016/j.jri.2015.02.004
37. Feng Y, Huang Q, Luo M, Wei J, Gao T, Chu D, et al. The association between Helicobacter pylori and gastrointestinal disorders during pregnancy: a multicenter retrospective study. Helicobacter. 2023. Available from: https://doi.org/10.1111/hel.13032
38. Tang Y, Yang Y, Lv Z. Adverse pregnancy outcomes and Helicobacter pylori infection: a meta-analysis. Int J Clin Pract. 2021. Available from: https://doi.org/10.1111/ijcp.14588
39. Chukwuma Sr C. Latent constraints for improved environmental health management in non-industrialised countries. Environ Manage Health. 1995;6(4):9-14. Available from: https://www.emerald.com/meq/article-abstract/6/4/9/27026/Latent-constraints-for-improved-sustainable?redirectedFrom=fulltext
40. Chukwuma Sr C. Environmental, developmental and health perspectives in Egypt. Environ Manage Health. 1995;6(1):38-46. Available from: doi:10.1108/09566169510078458.
41. Chukwuma Sr C. Social welfare and population dynamics in Egypt with particular reference to the status of women. Int J Environ Educ Inf. 1995;14(1):45-62. Available from: https://eric.ed.gov/?q=source%3A%22Journal+of+Environmental+Education%22&ff1=locEgypt&id=EJ505647
42. Nandkumar NA, Chakrala AA. Helicobacter pylori as a cause of iron deficiency in a menstruating woman in a primary care setting. Cureus. 2026. Available from: https://www.cureus.com/articles/365048-helicobacter-pylori-as-a-cause-of-iron-deficiency-in-a-menstruating-woman-in-a-primary-care-setting
43. Semeya AA, Abdel Hafez RSA, Al-Mihy NF, Elgamal R, Othman AAA. Vonoprazan-based triple therapy for Helicobacter pylori resistant to first-line regimens: a guideline-compliant 14-day multicenter study in Egypt. J Infect Public Health. 2026;19(1):103015. Available from: https://doi.org/10.1016/j.jiph.2025.103015
44. Mabeku LBK, Foguieng KNP, Mewa JEK, et al. Rate of Helicobacter pylori acquisition in children and evidence of mother-child transmission in a Sub-Saharan setting. Future Sci OA. 2025;11(1):2482497. Available from: https://doi.org/10.1080/20565623.2025.2482497
45. Wongcha-Um A, Thongkongthun T, Vilaichone R, Mahachai V. Helicobacter pylori: pathogenesis, clinical impact, and modern treatment approaches. In: Helicobacter pylori - Diagnosis, pathogenesis, and treatment strategies. London: IntechOpen; 2025. Available from: doi:10.5772/intechopen.1011730.
46. Chaves LC, Borges IK, Souza MD, Silva IP, Silva LB, Magalhães MA, et al. Inflammatory Helicobacter pylori in the Roux-en-Y bypass gastric pouch. Arq Bras Cir Dig. 2016;29 Suppl 1:31-34. Available from: https://doi.org/10.1590/0102-6720201600s10009
47. Hartin CW Jr, ReMine DS, Lucktong TA. Preoperative bariatric screening and treatment of Helicobacter pylori. Surg Endosc. 2009;23:2531-2534. Available from: https://doi.org/10.1007/s00464-009-0449-8
48. Chukwuma Sr C. Perspectives on the role of bioengineering for sustainable development in the health of women. Mathews J Gynecol Obstet. 2026;10(1):51. Available from: https://www.researchgate.net/publication/401065273_Perspectives_on_the_Role_of_Bioengineering_for_Sustainable_Development_in_the_Health_of_Women
49. Ness A, Levi Z, Belfer RG, et al. Helicobacter pylori eradication among adults receiving semaglutide: a population-based propensity-score-adjusted analysis. Helicobacter. 2025;30(1):e70014. Available from: https://doi.org/10.1111/hel.70014
50. Chukwuma Sr C. Perspectives in the emergence and re-emergence of infectious diseases, geopolitics and gain-of-function research. Sch Int J Biochem. 2022;5(1):1-7. Available from: https://www.researchgate.net/publication/357662437_Perspectives_in_the_Emergence_and_Re-Emergence_of_Infectious_Diseases_Geopolitics_and_Gain-of-Function_Research
51. Chukwuma Sr C. Geopolitics of the nature and crises of the environment, economics and health in a sustainable society for human progress and survival. J Sci Innov Res. 2024;13(1):3. Available from: doi:10.31254/jsir.2024.13103.
52. Chukwuma Sr C. Perspectives for a sustainable society. Environ Manage Health. 1996;7(5):6-20. Available from: https://www.emerald.com/meq/article-abstract/7/5/5/34979/Perspectives-for-a-sustainable-society?redirectedFrom=fulltext
53. Chukwuma Sr C. Geopolitical and public health spheres of GLP-1 receptor agonists usage of therapies in diabetes, obesity and other correlated pathological conditions. Jpn J Med Sci Res. 2026;1(1):1-8.
54. Chukwuma Sr C. Public health spheres of GLP-1 receptor agonists usage as therapies in diabetes and obesity subjects. J Int Med Health Sci. 2026;1(1).
55. Chukwuma Sr C. A composite function on the integration of technology management and care: targeting sepsis for quality of life and mitigation of morbidity and mortality. World J Pharm Healthc Res. 2026:1-11. Available from: doi:10.5281/zenodo.20502147.
56. Chukwuma Sr C. Approaches in diverse issues of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in global health strategy, economic burden, geopolitical implications and gain-of-function research. World J Pharm Healthc Res. 2025. Available from: doi:10.5281/zenodo.17510578.
57. Chukwuma Sr C. The challenges, issues and opportunities of GLP-1/GLP receptor agonists in research and patient care. J Curr Trends Clin Case Rep. 2025;6(3):1-12. Available from: https://www.katalystpublishers.com/uploads/journals/ai/the-challenges-issues-and-opportunities-of-glp1glp-receptor-agonists-in-research-and-patient-care590232.pdf
58. Diamond MP. Clinical implications of postsurgical adhesions. Hum Reprod Update. 2001;7(6):567-576. Available from: https://doi.org/10.1093/humupd/7.6.567
59. Beksac K, Donmez HG, Cagan M, et al. Is gastroesophageal reflux linked to inflammation-related gestational complications and poor obstetric history? BMC Pregnancy Childbirth. 2026;26:143. Available from: https://doi.org/10.1186/s12884-026-08640-1
60. Elbehiry A, Marzouk E. Helicobacter pylori eradication in the era of antibiotic resistance: from universal regimens to precision-guided management. Antibiotics (Basel). 2026;15(7):673. Available from: https://doi.org/10.3390/antibiotics15070673
61. Miranda J, Maestre N, Devia M, et al. Inflammation at the maternal-fetal interface: mechanisms linking maternal-fetal immunity to preeclampsia and fetal growth restriction. Int J Mol Sci. 2026;27(9):3954. Available from: https://doi.org/10.3390/ijms27093954
62. Niwińska KE, Michał N, Borowski J, et al. The impact of GLP-1 analogues and tirzepatide on female fertility: mechanisms, clinical evidence, and implications. J Educ Health Sport. 2026;87:67444. Available from: doi:10.12775/JEHS.2026.87.67444.
63. Chukwuma Sr C. Ecological analysis in diplomacy, geopolitics and international cooperation: driving accountability for social impact. Int J Frontline Res Multidiscip Stud. 2022;1(1):22-34. Available from: doi:10.56355/ijfrms.2022.1.1.0030.